Design Optimization in Nonlinear Mixed Effects Models Using Cost Functions: Application to a Joint Model of Infliximab and Methotrexate Pharmacokinetics

We address the problem of design optimization using cost functions in nonlinear mixed effects models with multiple responses. We focus on the relative feasibility of the optimized designs, in term of sampling times and of number of subjects. To do that, we extend the Fedorov–Wynn algorithm—a dedicated design optimization algorithm—to include a cost function that penalizes less feasible designs as well as to take into account multiple responses. We apply this extension to the design optimization of a joint pharmacokinetic model of infliximab and methotrexate administered in rheumatoid arthritis. We show the benefit of such an approach when substantial constraints on the design are imposed.

[1]  F Mentré,et al.  Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. , 2005, British journal of clinical pharmacology.

[2]  Mats O. Karlsson,et al.  Comparison of some practical sampling strategies for population pharmacokinetic studies , 1996, Journal of Pharmacokinetics and Biopharmaceutics.

[3]  Ulrich Klotz,et al.  Clinical Pharmacokinetics and Use of Infliximab , 2007, Clinical pharmacokinetics.

[4]  L. Sheiner,et al.  Modelling of individual pharmacokinetics for computer-aided drug dosage. , 1972, Computers and biomedical research, an international journal.

[5]  Brian Whiting,et al.  Experimental design and efficient parameter estimation in population pharmacokinetics , 1990, Journal of Pharmacokinetics and Biopharmaceutics.

[6]  P. Lipsky,et al.  Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. , 2000, The Journal of rheumatology.

[7]  F. Breedveld,et al.  Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[8]  Marc Lavielle,et al.  Maximum likelihood estimation in nonlinear mixed effects models , 2005, Comput. Stat. Data Anal..

[9]  Sergei Leonov,et al.  OPTIMAL POPULATION DESIGNS FOR PK MODELS WITH SERIAL SAMPLING , 2004, Journal of biopharmaceutical statistics.

[10]  Paolo Vicini,et al.  Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments , 2005, The AAPS Journal.

[11]  France Mentré,et al.  Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model , 2006, Comput. Stat. Data Anal..

[12]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[13]  Eric Walter,et al.  Identification of Parametric Models: from Experimental Data , 1997 .

[14]  France Mentré,et al.  Further Developments of the Fisher Information Matrix in Nonlinear Mixed Effects Models with Evaluation in Population Pharmacokinetics , 2003, Journal of biopharmaceutical statistics.

[15]  F J Lewis,et al.  Continuous patient monitoring with a small digital computer. , 1972, Computers and biomedical research, an international journal.

[16]  France Mentré,et al.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..

[17]  Malcolm Rowland,et al.  Optimal Design for Multivariate Response Pharmacokinetic Models , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[18]  A. Mallet A maximum likelihood estimation method for random coefficient regression models , 1986 .

[19]  Valerii V. Fedorov,et al.  Design of experiments with unknown parameters in variance , 2002 .

[20]  E. Keystone,et al.  The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[21]  France Mentré,et al.  Optimization of Individual and Population Designs Using Splus , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[22]  Goonaseelan Pillai,et al.  Non-Linear Mixed Effects Modeling – From Methodology and Software Development to Driving Implementation in Drug Development Science , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[23]  W. Näther Optimum experimental designs , 1994 .

[24]  D. Bates,et al.  Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model , 1995 .

[25]  France Mentré,et al.  Design in nonlinear mixed effects models: Optimization using the Fedorov–Wynn algorithm and power of the Wald test for binary covariates , 2007, Statistics in medicine.

[26]  W. J. Studden,et al.  Theory Of Optimal Experiments , 1972 .

[27]  France Mentré,et al.  Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics , 2002, Statistics in medicine.

[28]  J. Kremer,et al.  The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. , 1998, British journal of clinical pharmacology.

[29]  T. Louis Finding the Observed Information Matrix When Using the EM Algorithm , 1982 .

[30]  M. Berger,et al.  Relative efficiency of unequal cluster sizes for variance component estimation in cluster randomized and multicentre trials , 2008, Statistical methods in medical research.